Princeton Baptist Medical Center First Hospital in Alabama to Deploy 7D Surgical’s Machine-Vision Image Guided Surgery (MvIGS) Technology

As hospitals around the world look for new and innovative ways to improve surgical outcomes and patient safety, Princeton Baptist Medical Center has taken a leap into the future with the installation of the 7D Surgical FLASH™ Navigation System for spinal and cranial procedures by being the first hospital in Alabama to deploy the technology.

This system virtually replaces standard fluoroscopy, providing the surgical team with a fast, accurate and radiation-free tool for the placement of spinal implants.

“Princeton Baptist Medical Center has always been proactive in ensuring that we have the right tools to protect our patients and enhance neurosurgical patient care, which is why we supported the purchase of the 7D Surgical FLASH Navigation System,” said Mike Neuendorf, Princeton CEO. “This important investment underscores our commitment to patient care and the communities we serve, for both advanced spinal and cranial procedures.”

The 7D Surgical FLASH Navigation System is the first and only platform that utilizes Machine-Vision Image Guided Surgery (MvIGS) technology. For the first-time, spine surgeons can guide their tools to the critical anatomy using sophisticated camera technology linked to a computer in the operating theater. The underlying technology is similar to what is used in the latest self-driving automobiles. Unlike time-consuming conventional image guided surgery (IGS) systems that depend on intraoperative radiation, this new MvIGS technology can achieve an incredibly fast surgical workflow for spine procedures, reducing operative time for patients and eliminating unnecessary radiation exposure.

“As a Neurosurgeon, the FLASH Navigation System technology provides me with enhanced precision when placing hardware in the spine, because I can see the anatomy in 3D,” said Resit Cezayirli M.D., an affiliated neurosurgeon at Princeton Baptist Medical Center. “I am proud to offer my patients the latest technology in spine surgery while eliminating unnecessary radiation still used in many hospitals.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version